STOCK TITAN

[Form 4] BioAtla, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Eric Sievers, Chief Medical Officer of BioAtla, Inc. (BCAB), reported a withholding transaction tied to vested restricted stock units. On 08/31/2025, 2,729 shares were withheld at an effective price of $0.4555 to satisfy income tax and withholding obligations related to prior RSU vesting. After the withholding, the filing shows 364,574 shares beneficially owned by Sievers. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing explicitly states this was a net settlement withholding, not an open-market sale.

Eric Sievers, Chief Medical Officer di BioAtla, Inc. (BCAB), ha segnalato un'operazione di ritenuta legata a restricted stock units venute a maturazione. Il 31/08/2025 sono state trattenute 2.729 azioni a un prezzo effettivo di $0,4555 per soddisfare obblighi fiscali e di ritenuta derivanti dal precedente vesting delle RSU. Dopo la ritenuta, la comunicazione indica che Sievers detiene beneficiariamente 364.574 azioni. Il Modulo 4 è stato firmato per procura il 02/09/2025. Il documento precisa che si è trattato di un regolamento netto tramite ritenuta, non di una vendita sul mercato aperto.

Eric Sievers, Director Médico de BioAtla, Inc. (BCAB), informó una operación de retención vinculada a unidades restringidas (RSU) que ya habían vencido. El 31/08/2025 se retuvieron 2.729 acciones a un precio efectivo de $0.4555 para cubrir obligaciones fiscales y de retención relacionadas con el vesting previo de las RSU. Tras la retención, la declaración muestra que Sievers posee beneficiosamente 364.574 acciones. El Formulario 4 fue firmado por un apoderado el 02/09/2025. El informe aclara que fue una compensación neta mediante retención y no una venta en el mercado abierto.

BioAtla, Inc. (BCAB)의 최고의료책임자(Chief Medical Officer)인 Eric Sievers는 기득권한 제한주식단위(RSU)와 관련된 원천징수 거래를 보고했습니다. 2025년 8월 31일, 이전 RSU의 베스팅에 따른 소득세 및 원천징수 의무를 충족하기 위해 2,729주가 유효가격 $0.4555로 원천징수되었습니다. 원천징수 후 해당 신고서에는 Sievers가 실질적으로 보유한 주식이 364,574주라고 기재되어 있습니다. 양식 4는 2025년 9월 2일에 대리인이 서명했습니다. 해당 신고서는 공개시장 매각이 아닌 순정산 방식의 원천징수였음을 명시합니다.

Eric Sievers, Chief Medical Officer de BioAtla, Inc. (BCAB), a déclaré une opération de retenue liée à des unités d'actions restreintes (RSU) acquises. Le 31/08/2025, 2 729 actions ont été retenues à un prix effectif de 0,4555 $ pour satisfaire aux obligations fiscales et de retenue liées au vesting antérieur des RSU. Après cette retenue, le dossier indique que Sievers détient à titre bénéficiaire 364 574 actions. Le formulaire 4 a été signé par un mandataire le 02/09/2025. Le dépôt précise qu'il s'agissait d'un règlement net par retenue, et non d'une vente sur le marché ouvert.

Eric Sievers, Chief Medical Officer von BioAtla, Inc. (BCAB), meldete eine Einbehaltstransaktion im Zusammenhang mit ausgeübten Restricted Stock Units. Am 31.08.2025 wurden 2.729 Aktien zu einem effektiven Preis von $0,4555 einbehalten, um Einkommenssteuer- und Einbehaltspflichten aus früherem RSU-Vesting zu erfüllen. Nach dem Einbehalt weist die Meldung einen wirtschaftlichen Besitz von 364.574 Aktien durch Sievers aus. Das Formular 4 wurde am 02.09.2025 von einem Bevollmächtigten unterzeichnet. In der Einreichung wird deutlich angegeben, dass es sich um eine Nettosettlement-Einbehaltung und nicht um einen Verkauf am offenen Markt handelte.

Positive
  • Clear disclosure of the withholding transaction and its purpose (tax and remittance on vested RSUs).
  • Compliance with Section 16 reporting shown by timely Form 4 submission and explanatory note.
Negative
  • None.

Insights

TL;DR: Routine insider withholding for taxes on vested RSUs; no sale proceeds and limited market impact.

This Form 4 documents a tax-withholding net settlement of previously granted restricted stock units. The withheld amount, 2,729 shares at $0.4555, reduces the reporting person’s post-transaction share count to 364,574. Because shares were withheld rather than sold on the open market, there is no direct change in share supply from a sale event. The disclosure complies with Section 16 reporting requirements and provides transparency on insider equity changes.

TL;DR: Standard compliance disclosure reflecting executive tax withholding on vested equity; governance signals are routine.

The filing indicates appropriate reporting of equity compensation settlement mechanics. Net settlement to cover tax obligations is a common mechanism for RSUs and the form clarifies the nature of the transaction. The signature by an attorney-in-fact is noted, and the explanation field clearly states the transaction was not a sale by the reporting person, which maintains clarity for shareholders reviewing insider activity.

Eric Sievers, Chief Medical Officer di BioAtla, Inc. (BCAB), ha segnalato un'operazione di ritenuta legata a restricted stock units venute a maturazione. Il 31/08/2025 sono state trattenute 2.729 azioni a un prezzo effettivo di $0,4555 per soddisfare obblighi fiscali e di ritenuta derivanti dal precedente vesting delle RSU. Dopo la ritenuta, la comunicazione indica che Sievers detiene beneficiariamente 364.574 azioni. Il Modulo 4 è stato firmato per procura il 02/09/2025. Il documento precisa che si è trattato di un regolamento netto tramite ritenuta, non di una vendita sul mercato aperto.

Eric Sievers, Director Médico de BioAtla, Inc. (BCAB), informó una operación de retención vinculada a unidades restringidas (RSU) que ya habían vencido. El 31/08/2025 se retuvieron 2.729 acciones a un precio efectivo de $0.4555 para cubrir obligaciones fiscales y de retención relacionadas con el vesting previo de las RSU. Tras la retención, la declaración muestra que Sievers posee beneficiosamente 364.574 acciones. El Formulario 4 fue firmado por un apoderado el 02/09/2025. El informe aclara que fue una compensación neta mediante retención y no una venta en el mercado abierto.

BioAtla, Inc. (BCAB)의 최고의료책임자(Chief Medical Officer)인 Eric Sievers는 기득권한 제한주식단위(RSU)와 관련된 원천징수 거래를 보고했습니다. 2025년 8월 31일, 이전 RSU의 베스팅에 따른 소득세 및 원천징수 의무를 충족하기 위해 2,729주가 유효가격 $0.4555로 원천징수되었습니다. 원천징수 후 해당 신고서에는 Sievers가 실질적으로 보유한 주식이 364,574주라고 기재되어 있습니다. 양식 4는 2025년 9월 2일에 대리인이 서명했습니다. 해당 신고서는 공개시장 매각이 아닌 순정산 방식의 원천징수였음을 명시합니다.

Eric Sievers, Chief Medical Officer de BioAtla, Inc. (BCAB), a déclaré une opération de retenue liée à des unités d'actions restreintes (RSU) acquises. Le 31/08/2025, 2 729 actions ont été retenues à un prix effectif de 0,4555 $ pour satisfaire aux obligations fiscales et de retenue liées au vesting antérieur des RSU. Après cette retenue, le dossier indique que Sievers détient à titre bénéficiaire 364 574 actions. Le formulaire 4 a été signé par un mandataire le 02/09/2025. Le dépôt précise qu'il s'agissait d'un règlement net par retenue, et non d'une vente sur le marché ouvert.

Eric Sievers, Chief Medical Officer von BioAtla, Inc. (BCAB), meldete eine Einbehaltstransaktion im Zusammenhang mit ausgeübten Restricted Stock Units. Am 31.08.2025 wurden 2.729 Aktien zu einem effektiven Preis von $0,4555 einbehalten, um Einkommenssteuer- und Einbehaltspflichten aus früherem RSU-Vesting zu erfüllen. Nach dem Einbehalt weist die Meldung einen wirtschaftlichen Besitz von 364.574 Aktien durch Sievers aus. Das Formular 4 wurde am 02.09.2025 von einem Bevollmächtigten unterzeichnet. In der Einreichung wird deutlich angegeben, dass es sich um eine Nettosettlement-Einbehaltung und nicht um einen Verkauf am offenen Markt handelte.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sievers Eric

(Last) (First) (Middle)
C/O BIOATLA, INC. 11085 TORREYANA ROAD

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BioAtla, Inc. [ BCAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/31/2025 F(1) 2,729 D $0.4555 364,574 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.
/s/ Christian Vasquez, as Attorney-in-Fact for Eric Sievers 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Eric Sievers report on Form 4 for BCAB?

He reported a net settlement withholding of 2,729 shares on 08/31/2025 related to vested restricted stock units.

Was the transaction a market sale of BCAB shares?

No. The filing states the shares were withheld by the issuer to satisfy tax and withholding obligations, not sold in the market.

How many BCAB shares does Eric Sievers beneficially own after the transaction?

The Form 4 reports 364,574 shares beneficially owned following the withholding.

At what price were the withheld BCAB shares recorded?

The withheld shares are shown at a price of $0.4555 per share.

Who signed the Form 4 filing for Eric Sievers and when?

The form was signed by Christian Vasquez, as Attorney-in-Fact for Eric Sievers on 09/02/2025.
Bioatla, Inc.

NASDAQ:BCAB

BCAB Rankings

BCAB Latest News

BCAB Latest SEC Filings

BCAB Stock Data

26.75M
52.22M
10.6%
29.76%
6.71%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO